What are the red flags that mean a soft tissue lump could be a sarcoma?

Any soft tissue lump that is greater than 5 cm, deep to the muscle layers (deep to fascia), growing rapidly, painful, or returning after a previous excision deserves urgent specialist review and MRI — not watchful waiting and not local removal. Most lumps are benign lipomas or cysts, but a sarcoma that is shelled out without proper staging is a catastrophe for limb salvage. The RACGP and Cancer Council Australia both endorse an urgent 2-week-pathway referral to a sarcoma multidisciplinary team for any lesion meeting these criteria, without attempting biopsy in general practice first.

Why must a GP never excise or biopsy a suspected sarcoma?

When a sarcoma is inadvertently shelled out in general practice or general surgery — the 'whoops' procedure — the surgical tract becomes contaminated with tumour cells, narrowing the margin available for definitive re-excision and often making limb salvage impossible. Multiple studies show worse local recurrence rates and poorer survival after unplanned excision. The correct biopsy is a core-needle biopsy performed at a sarcoma specialist centre, image-guided through a tract aligned with the planned definitive surgical incision so the entire biopsy tract can be excised as part of the final operation — this is why the receiving centre must do it, not the referrer.

What is GIST and how is it treated in Australia?

Gastrointestinal stromal tumour (GIST) is the most common mesenchymal tumour of the GI tract, driven by KIT or PDGFRA mutations. It presents as incidental imaging finding, GI bleeding, or abdominal mass. Imatinib (Glivec) transformed outcomes for unresectable or metastatic GIST in 2001, with durable responses where previously none existed. Resectable GIST is treated with surgery; high-risk patients receive three years of adjuvant imatinib per PBS Authority Section 100. Lines two through four (sunitinib, regorafenib, ripretinib) are PBS-listed sequentially. GP role is to suspect the diagnosis on imaging, arrange urgent referral, and support long-term medication adherence.

What causes sarcoma and who is at highest risk?

Most sarcomas arise sporadically without a clearly identified cause. Known risk factors include inherited syndromes — Li-Fraumeni (TP53), retinoblastoma (RB1), and neurofibromatosis type 1 (NF1, which confers up to 13% lifetime risk of malignant peripheral nerve sheath tumour and small-bowel GIST); prior radiotherapy to a field (post-radiation sarcoma typically emerges 5–15 years later); chronic lymphoedema after axillary surgery (Stewart-Treves angiosarcoma); and Paget's disease of bone in older adults. Bone sarcomas disproportionately affect young people — osteosarcoma and Ewing sarcoma both peak at 15–30 years, making unexplained bone pain in an adolescent or young adult a priority presentation.

What ongoing care does a sarcoma survivor need from their GP?

Sarcoma has a high risk of local recurrence and lung metastases — the sarcoma centre coordinates surveillance imaging (CT chest and MRI primary site) typically every 3 months for 2–3 years, then 6-monthly to 5 years. GP role in survivorship includes monitoring for cardiotoxicity in anthracycline-treated patients (serial echocardiography), managing lymphoedema after limb-salvage surgery, supporting fertility concerns in young adults treated with chemotherapy, screening for mental health distress (especially in adolescents and young adults), and triggering genetic cascade counselling for families with Li-Fraumeni, NF1, or familial GIST.

Sarcoma

Sarcoma: recognising red flags and avoiding the unplanned excision

By Dr HB Lo, FACRRM Reviewed 10 October 2026 7 min read

Sarcomas are rare mesenchymal malignancies — soft tissue (~80%) and bone (~20%) — totalling ~3,000 cases per year in Australia (1% of all cancers). The GP's two critical roles: recognise red flags and never excise. Red flags: any mass greater than 5 cm, deep to fascia, rapidly growing, painful, or recurring after prior excision; unexplained bone pain, especially at night, in any age group. Never excise or biopsy a suspected sarcoma in general practice — the 'whoops procedure' (unplanned excision) worsens margins and limb-salvage outcomes. All suspected cases go directly to a sarcoma multidisciplinary team for image-guided core-needle biopsy.

Sarcoma is the umbrella term for a family of more than 70 malignancies of mesenchymal origin — connective tissue, fat, muscle, blood vessels, nerves, and bone. They are rare, accounting for roughly 1% of adult cancers in Australia, but their rarity is precisely why they are dangerous in general practice: a lump that looks and feels like a benign lipoma may not be, and the wrong response — local excision — can cost a patient their limb.

The Australian Institute of Health and Welfare (AIHW) reports approximately 3,000 new sarcoma diagnoses per year in Australia — around 2,400 soft tissue sarcomas (STS) and 600 bone sarcomas. Five-year relative survival varies widely by subtype and stage: STS ~65%, osteosarcoma ~70%, Ewing sarcoma ~55%, and advanced or metastatic disease ~20%. Delays in diagnosis are the rule rather than the exception, with median time from symptom onset to diagnosis often exceeding four months in population-based audits.

The general practitioner’s contribution to sarcoma outcomes is concentrated in a single decision: recognise the red flags, make the referral, and do not attempt to remove the mass. Everything else follows from that moment.

A. Core clinical — the AU general-practice framework

Red flags — when to act urgently

The RACGP and Cancer Council Australia define a 2-week-pathway sarcoma MDT referral as appropriate for any patient presenting with:

A soft tissue mass greater than 5 cm in any location.
A mass deep to the deep fascia (not freely mobile within the skin/subcutaneous fat).
A mass that is rapidly growing over weeks to months.
A mass that is painful (lipomas are generally not tender).
A mass that has recurred after prior excision — especially if the histology from that excision was uncertain or reassuring.
Persistent unexplained bone pain not relieved by rest, particularly night pain, in any age group.
A palpable bone mass or an X-ray showing lytic, sclerotic, sunburst, or moth-eaten changes.
A new or growing soft tissue lesion in a patient with NF1 — malignant peripheral nerve sheath tumour (MPNST) risk is up to 13% lifetime.

History

Focused assessment should capture: onset and growth trajectory; associated pain (sarcomas may be painless early); depth relative to fascia; any prior excision or biopsy; relevant risk factors (prior radiotherapy, chronic lymphoedema, NF1, family history of Li-Fraumeni/retinoblastoma); bone symptoms (night pain, limp, pathological fracture); systemic features (weight loss, night sweats — more prominent in Ewing sarcoma than in STS); and psychosocial context for adolescents and young adults.

Examination

For soft tissue lesions: measure size with callipers and document; assess depth (mobile within skin = superficial; tethered to muscle = deep); assess overlying skin, regional lymphadenopathy (unusual but relevant in epithelioid sarcoma, synovial sarcoma), and neurovascular status. Inspect for café-au-lait spots and neurofibromas (NF1). For bone lesions: localise tenderness precisely; assess range of motion; palpate for mass; perform respiratory examination for lung metastasis.

Investigations before referral

Order a plain radiograph for any persistent bone pain — lytic lesion, Codman triangle, periosteal sunburst, or “moth-eaten” cortex on a plain film is a red flag requiring urgent sarcoma referral. Take a photograph with a measurement scale. Check FBC, LDH, ESR, and alkaline phosphatase — LDH and ALP are prognostic in osteosarcoma; inflammatory markers may be elevated in Ewing sarcoma. Do not arrange MRI or attempt biopsy yourself — these are done by the receiving sarcoma centre, where the MRI field and biopsy tract are planned together to minimise surgical contamination.

The critical rule: never perform an unplanned excision

Lin et al. (Ann Surg Oncol 2008) and Pretell-Mazzini et al. (JCO 2015) documented that unplanned excision accounts for 25–50% of sarcoma referrals to specialist centres and is independently associated with worse local control, limb-salvage failure, and reduced overall survival. The biopsy tract must be excised en bloc with the tumour during definitive surgery — if that tract runs in the wrong plane, the entire surgical field is compromised. Refer first; the sarcoma centre arranges the biopsy.

B. Evidence appraisal — treatment and key trials

Soft tissue sarcoma

Per NCCN STS v.2.2024 and ESMO sarcoma guidelines, the cornerstone of localised STS treatment is wide surgical resection with negative margins (R0), combined with adjuvant radiotherapy for high-grade or close-margin disease. Adjuvant chemotherapy with doxorubicin and ifosfamide offers a modest survival benefit in high-grade chemosensitive subtypes (synovial sarcoma, high-grade extremity STS) per the EORTC-STBSG meta-analysis (Le Cesne, JCO 2014). For metastatic non-adipocytic STS, pazopanib prolongs progression-free survival per the PALETTE trial (van der Graaf, Lancet 2012) — it is PBS-listed after anthracycline failure.

GIST

The B2222 trial (Demetri GD, NEJM 2002) established imatinib as transformative for advanced GIST — durable responses in a disease previously with no effective systemic therapy. The SSG-XVIII trial (Joensuu H, JAMA 2012) confirmed three years of adjuvant imatinib for high-risk resected GIST — 5-year recurrence-free survival 65.6% vs 47.9% with one year. PBS Authority Section 100 covers imatinib first-line, sunitinib second-line, regorafenib third-line, and ripretinib fourth-line.

Bone sarcomas

Osteosarcoma is treated with MAP chemotherapy (high-dose methotrexate, doxorubicin, cisplatin) plus limb-salvage surgery. Ewing sarcoma uses interval-compressed VDC-IE (vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide, etoposide). Both regimens are delivered at eviQ-approved sarcoma specialist centres. For NTRK fusion-positive sarcomas (and other solid tumours), larotrectinib (Vitrakvi) achieves durable responses and is PBS-listed under Authority Section 100.

C. Recognising subtypes by presentation

Most common STS subtypes a GP may encounter on imaging reports or referral letters: liposarcoma (well-differentiated large retroperitoneal or extremity mass), leiomyosarcoma (uterine primary; or soft-tissue), undifferentiated pleomorphic sarcoma (UPS, older adults, often post-radiotherapy or de novo), dermatofibrosarcoma protuberans (DFSP — slow-growing, skin-tethered, low-grade; excision with wide margins curative; not a “whoops” candidate), and angiosarcoma (scalp or chest wall in older women post-irradiation).

Bone sarcoma clues:

Osteosarcoma — adolescent or young adult, distal femur or proximal tibia metaphysis, night pain, X-ray periosteal reaction.
Ewing sarcoma — adolescent/young adult, diaphysis of long bones or flat bones (pelvis/ribs), fever, elevated ESR, may look like osteomyelitis.
Chondrosarcoma — older adult (>50), pelvis or ribs, slow-growing, relatively chemo/radioresistant.
Secondary osteosarcoma — older adult with known Paget’s disease developing acute change.

GIST presentation: incidental finding on CT or colonoscopy; or GI bleeding, early satiety, palpable mass; most commonly gastric or small intestinal origin. Always refer for specialist workup if KIT/PDGFRA-positive on biopsy report.

D. Australian operations

The Australian Sarcoma Study Group (ASSG) operates a national multidisciplinary team network at designated tertiary sarcoma centres: Peter MacCallum / Royal Melbourne Hospital, Royal North Shore Sydney, Princess Alexandra Brisbane, Royal Adelaide Hospital, and Sir Charles Gairdner Perth — with regional referral pathways from rural and remote settings.

MBS items for GP coordination: standard consultations 23, 36, 44 — typically Level C/D given complexity; GPCCMP 965/967 for active cancer management; MHCP 2715/2717 for psychological distress; ATSI health assessment 715; cardiotoxicity echo 55113 for anthracycline survivors; telehealth 91790/91891 for rural patients linking to centralised sarcoma centres.

PBS authority drugs: imatinib, sunitinib, regorafenib, ripretinib, pazopanib, trabectedin, larotrectinib, and entrectinib are all PBS Section 100 Authority-listed for their relevant sarcoma indications; specialist-initiated with long-term GP supply for ongoing prescriptions. Bone-modifying agents (zoledronic acid, denosumab) are Authority-listed for bone metastases.

Genetic testing: MBS items 73296/73297 cover germline testing for Li-Fraumeni/TP53, RB1, and NF1 — refer to clinical genetics for cascade counselling.

ATSI considerations: Aboriginal and Torres Strait Islander patients referred to centralised sarcoma centres may face significant travel burdens — engage the Aboriginal Liaison Officer early and access IPTAAS (NSW) or the Patient Assisted Travel Scheme (PATS) equivalent in other states.

E. Special populations

Adolescents and young adults (AYA). Osteosarcoma and Ewing sarcoma disproportionately affect 15–30 year olds. Fertility preservation before chemotherapy is time-critical — refer reproductive endocrinology before treatment starts. AYA-specific psychosocial support, peer networks (Sarcoma Australia AYA program), and vocational rehabilitation are essential.

NF1. Any new or enlarging soft tissue lesion in an NF1 patient, or a plexiform neurofibroma with sudden growth, new pain, or new neurological deficit, should be treated as MPNST until proven otherwise by specialist imaging and biopsy. NF1-associated GIST is typically KIT/PDGFRA wild-type and imatinib-refractory.

Prior radiotherapy. Post-radiation sarcoma (usually UPS or angiosarcoma) emerges in the radiation field 5–15 years after treatment. Any new mass in a previously irradiated area deserves MRI and sarcoma MDT referral, regardless of size.

Older adults with Paget’s disease. Secondary osteosarcoma may develop in a Paget’s lesion — sudden increase in pain, new swelling, or rising ALP warrants urgent imaging and referral.

Pregnancy. Sarcoma during pregnancy is exceptionally rare; all cases require joint oncology and obstetric specialist management. Fertility considerations apply post-treatment in young women.

When to escalate

Refer same-day to ED for: suspected pathological fracture; acute spinal cord compression (back pain with progressive neurological deficit); neutropenic sepsis or fever while on chemotherapy.

Refer urgently (within 24–48 h) to sarcoma MDT for all red-flag presentations listed above. When in doubt, the Australian Sarcoma Study Group provides specialist triage advice.

Cascade family members to clinical genetics for Li-Fraumeni, retinoblastoma, NF1, and familial GIST — do not wait for the index patient’s treatment to be complete.

What this article is and is not

This is general health information drawn from current Australian guidelines — AIHW, ASSG, Therapeutic Guidelines (eTG), RACGP, Cancer Council Australia, NCCN, and ESMO. It is not personal medical advice and does not replace specialist assessment.

For Australian consumer-friendly information: Sarcoma Australia, Cancer Council 13 11 20, HealthDirect.

Sources cited

Frequently asked questions

What are the red flags that mean a soft tissue lump could be a sarcoma?

Any soft tissue lump that is greater than 5 cm, deep to the muscle layers (deep to fascia), growing rapidly, painful, or returning after a previous excision deserves urgent specialist review and MRI — not watchful waiting and not local removal. Most lumps are benign lipomas or cysts, but a sarcoma that is shelled out without proper staging is a catastrophe for limb salvage. The RACGP and Cancer Council Australia both endorse an urgent 2-week-pathway referral to a sarcoma multidisciplinary team for any lesion meeting these criteria, without attempting biopsy in general practice first.
Why must a GP never excise or biopsy a suspected sarcoma?

When a sarcoma is inadvertently shelled out in general practice or general surgery — the 'whoops' procedure — the surgical tract becomes contaminated with tumour cells, narrowing the margin available for definitive re-excision and often making limb salvage impossible. Multiple studies show worse local recurrence rates and poorer survival after unplanned excision. The correct biopsy is a core-needle biopsy performed at a sarcoma specialist centre, image-guided through a tract aligned with the planned definitive surgical incision so the entire biopsy tract can be excised as part of the final operation — this is why the receiving centre must do it, not the referrer.
What is GIST and how is it treated in Australia?

Gastrointestinal stromal tumour (GIST) is the most common mesenchymal tumour of the GI tract, driven by KIT or PDGFRA mutations. It presents as incidental imaging finding, GI bleeding, or abdominal mass. Imatinib (Glivec) transformed outcomes for unresectable or metastatic GIST in 2001, with durable responses where previously none existed. Resectable GIST is treated with surgery; high-risk patients receive three years of adjuvant imatinib per PBS Authority Section 100. Lines two through four (sunitinib, regorafenib, ripretinib) are PBS-listed sequentially. GP role is to suspect the diagnosis on imaging, arrange urgent referral, and support long-term medication adherence.
What causes sarcoma and who is at highest risk?

Most sarcomas arise sporadically without a clearly identified cause. Known risk factors include inherited syndromes — Li-Fraumeni (TP53), retinoblastoma (RB1), and neurofibromatosis type 1 (NF1, which confers up to 13% lifetime risk of malignant peripheral nerve sheath tumour and small-bowel GIST); prior radiotherapy to a field (post-radiation sarcoma typically emerges 5–15 years later); chronic lymphoedema after axillary surgery (Stewart-Treves angiosarcoma); and Paget's disease of bone in older adults. Bone sarcomas disproportionately affect young people — osteosarcoma and Ewing sarcoma both peak at 15–30 years, making unexplained bone pain in an adolescent or young adult a priority presentation.
What ongoing care does a sarcoma survivor need from their GP?

Sarcoma has a high risk of local recurrence and lung metastases — the sarcoma centre coordinates surveillance imaging (CT chest and MRI primary site) typically every 3 months for 2–3 years, then 6-monthly to 5 years. GP role in survivorship includes monitoring for cardiotoxicity in anthracycline-treated patients (serial echocardiography), managing lymphoedema after limb-salvage surgery, supporting fertility concerns in young adults treated with chemotherapy, screening for mental health distress (especially in adolescents and young adults), and triggering genetic cascade counselling for families with Li-Fraumeni, NF1, or familial GIST.

Source quality

Sources grouped by evidence tier. AU primary tier first; international where AU is silent or lagging; named-author reconstruction where guidelines have not yet caught up. How tiers work.